| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Vol. 51, Issue 4, 745-781, December 1999
Institut National de la Santé et de la Recherche
Médicale U266, Centre National de la Recherche Scientifique UMR
8600, Université René Descartes, Paris, France (B.P.R.,
F.N.); Royal Ottawa Hospital, University of Ottawa, Ottawa, Ontario,
Canada (J.B.); Section on Behavioral Neuropharmacology, Experimental
Therapeutics Branch, National Institute of Mental Health, Bethesda,
Maryland (J.N.C.); National Institutes of Health, Digestive
Diseases Branch, Bethesda, Maryland (S.A.W.); Department of Anatomy and
Neurobiology, Chandler Medical Center, University of Kentucky,
Lexington, Kentucky (K.B.S.); and Institut National de la Santé
et de la Recherche Médicale U288, Faculté de Médecine
Pitié-Salpêtrière, Paris, France (M.H.)
I. Introduction
II. Characterization of Cholecystokinin (CCK) Receptors
A. CCK1 (CCK-A) Receptors
1. CCK1 Receptor Clones.
2. Antagonists of CCK1 Receptors.
3. Agonists of CCK1 Receptors.
B. CCK2 (CCK-B) Receptors
1. CCK2 Receptor Clones.
2. Gastrin Receptors Are CCK2 Receptors.
3. Antagonists of CCK2 Receptors.
4. Agonists of CCK2 Receptors.
III. Molecular Biology of CCK Receptors
A. CCK Receptor Gene Structure
B. Chromosomal Localization of CCK Receptor Genes
C. Animal Models without Detectable Levels of CCK Receptors
IV. Receptor Structure/Function Studies
A. Signal Transduction
1. CCK1 Receptors.
2. CCK2 Receptors.
B. Ligand-Receptor Interaction
1. Agonists.
2. Antagonists.
C. Receptor Regulation.
V. Radioligands and Binding Assays: Heterogeneity of
CCK1 and CCK2 Receptors
A. Radioligands at CCK1 Receptors
B. Radioligands at CCK2 Receptors
C. Heterogeneity of CCK2 Receptor-Binding Sites
VI. Distribution of CCK Receptors
A. Distribution in Central Nervous System
1. CCK1 Receptors.
2. CCK2 Receptors.
3. Regulation of CCK Receptors.
B. Distribution in Gastrointestinal and Other Systems
VII. Physiological Implications of CCK Receptors
A. Peripheral Functions
B. Central Functions
1. CCK in Panic Attacks and Anxiety.
2. CCK and Schizophrenia.
3. CCK and Depression.
4. CCK and Memory Processes.
5. Interactions between CCK and Enkephalin
Systems.
VIII. Conclusion
Acknowledgments
References
This article has been cited by other articles:
|
|
 |
|
  H. L. Ashurst, A. Varro, and R. Dimaline Regulation of mammalian gastrin/CCK receptor (CCK2R) expression in vitro and in vivo Exp Physiol, February 1, 2008; 93(2): 223 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Morton, T. D. Barrett, W. Yan, J. M. Freedman, G. Lagaud, C. E. Prendergast, V. Moreno, J. Pyati, K. Figueroa, L. Li, et al. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a Novel, Potent, and Selective Cholecystokinin 1 Receptor Antagonist: In Vitro and in Vivo Pharmacological Comparison with Dexloxiglumide J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 562 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Marco, M. Foucaud, I. Langer, C. Escrieut, I. G. Tikhonova, and D. Fourmy Mechanism of Activation of a G Protein-coupled Receptor, the Human Cholecystokinin-2 Receptor J. Biol. Chem., September 28, 2007; 282(39): 28779 - 28790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Oz, K.-H. Yang, T. S. Shippenberg, L. P. Renaud, and M. J. O'Donovan Cholecystokinin B-Type Receptors Mediate a G-Protein-Dependent Depolarizing Action of Sulphated Cholecystokinin Ocatapeptide (CCK-8s) on Rodent Neonatal Spinal Ventral Horn Neurons J Neurophysiol, September 1, 2007; 98(3): 1108 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wan, F. H. Coleman, and R. A. Travagli Cholecystokinin-8s excites identified rat pancreatic-projecting vagal motoneurons Am J Physiol Gastrointest Liver Physiol, August 1, 2007; 293(2): G484 - G492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dimaline and A. Varro Attack and defence in the gastric epithelium a delicate balance Exp Physiol, July 1, 2007; 92(4): 591 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Clerc, M. G. Coll Constans, H. Lulka, S. Broussaud, C. Guigne, S. Leung-Theung-Long, C. Perrin, C. Knauf, C. Carpene, L. Penicaud, et al. Involvement of Cholecystokinin 2 Receptor in Food Intake Regulation: Hyperphagia and Increased Fat Deposition in Cholecystokinin 2 Receptor-Deficient Mice Endocrinology, March 1, 2007; 148(3): 1039 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Wang and Z. J. Cui How does cholecystokinin stimulate exocrine pancreatic secretion? From birds, rodents, to humans Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R666 - R678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Giacobini and S. Wray Cholecystokinin Directly Inhibits Neuronal Activity of Primary Gonadotropin-Releasing Hormone Cells through Cholecystokinin-1 Receptor Endocrinology, January 1, 2007; 148(1): 63 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Weiland, N. J. Voudouris, and S. Kent CCK2 receptor nullification attenuates lipopolysaccharide-induced sickness behavior Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R112 - R123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Benedetti, M. Amanzio, S. Vighetti, and G. Asteggiano The Biochemical and Neuroendocrine Bases of the Hyperalgesic Nocebo Effect. J. Neurosci., November 15, 2006; 26(46): 12014 - 12022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Harikumar, D. I. Pinon, and L. J. Miller Fluorescent Indicators Distributed throughout the Pharmacophore of Cholecystokinin Provide Insights into Distinct Modes of Binding and Activation of Type A and B Cholecystokinin Receptors J. Biol. Chem., September 15, 2006; 281(37): 27072 - 27080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dufresne, C. Seva, and D. Fourmy Cholecystokinin and gastrin receptors. Physiol Rev, July 1, 2006; 86(3): 805 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Foucaud, I. G. Tikhonova, I. Langer, C. Escrieut, M. Dufresne, C. Seva, B. Maigret, and D. Fourmy Partial Agonism, Neutral Antagonism, and Inverse Agonism at the Human Wild-Type and Constitutively Active Cholecystokinin-2 Receptors Mol. Pharmacol., March 1, 2006; 69(3): 680 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schulz, C. Rocken, C. Mawrin, and S. Schulz Immunohistochemical Localization of CCK1 Cholecystokinin Receptors in Normal and Neoplastic Human Tissues J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6149 - 6155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tsujino, A. Yamanaka, K. Ichiki, Y. Muraki, T. S. Kilduff, K.-i. Yagami, S. Takahashi, K. Goto, and T. Sakurai Cholecystokinin Activates Orexin/Hypocretin Neurons through the Cholecystokinin A Receptor J. Neurosci., August 10, 2005; 25(32): 7459 - 7469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Langer, I. G. Tikhonova, M.-A. Travers, E. Archer-Lahlou, C. Escrieut, B. Maigret, and D. Fourmy Evidence That Interspecies Polymorphism in the Human and Rat Cholecystokinin Receptor-2 Affects Structure of the Binding Site for the Endogenous Agonist Cholecystokinin J. Biol. Chem., June 10, 2005; 280(23): 22198 - 22204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Morel, G. Ibarz, C. Oiry, E. Carnazzi, G. Berge, D. Gagne, J.-C. Galleyrand, and J. Martinez Cross-interactions of Two p38 Mitogen-activated Protein (MAP) Kinase Inhibitors and Two Cholecystokinin (CCK) Receptor Antagonists with the CCK1 Receptor and P38 MAP Kinase J. Biol. Chem., June 3, 2005; 280(22): 21384 - 21393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dong, E. M. Hadac, D. I. Pinon, and L. J. Miller Differential Spatial Approximation between Cholecystokinin Residue 30 and Receptor Residues in Active and Inactive Conformations Mol. Pharmacol., June 1, 2005; 67(6): 1892 - 1900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zheng, M. W. Lewis, and R. A. Travagli In vitro analysis of the effects of cholecystokinin on rat brain stem motoneurons Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G1066 - G1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Archer-Lahlou, C. Escrieut, P. Clerc, J. Martinez, L. Moroder, C. Logsdon, A. Kopin, C. Seva, M. Dufresne, L. Pradayrol, et al. Molecular Mechanism Underlying Partial and Full Agonism Mediated by the Human Cholecystokinin-1 Receptor J. Biol. Chem., March 18, 2005; 280(11): 10664 - 10674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Reidelberger, J. Hernandez, B. Fritzsch, and M. Hulce Abdominal vagal mediation of the satiety effects of CCK in rats Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2004; 286(6): R1005 - R1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Giacobini, A. S. Kopin, P. M. Beart, L. D. Mercer, A. Fasolo, and S. Wray Cholecystokinin Modulates Migration of Gonadotropin-Releasing Hormone-1 Neurons J. Neurosci., May 19, 2004; 24(20): 4737 - 4748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mazzocchi, L. K. Malendowicz, F. Aragona, R. Spinazzi, and G. G. Nussdorfer Cholecystokinin (CCK) Stimulates Aldosterone Secretion from Human Adrenocortical Cells via CCK2 Receptors Coupled to the Adenylate Cyclase/Protein Kinase A Signaling Cascade J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1277 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Beinborn, Y. Ren, M. Blaker, C. Chen, and A. S. Kopin Ligand Function at Constitutively Active Receptor Mutants Is Affected by Two Distinct Yet Interacting Mechanisms Mol. Pharmacol., March 1, 2004; 65(3): 753 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gales, M. Poirot, J. Taillefer, B. Maigret, J. Martinez, L. Moroder, C. Escrieut, L. Pradayrol, D. Fourmy, and S. Silvente-Poirot Identification of Tyrosine 189 and Asparagine 358 of the Cholecystokinin 2 Receptor in Direct Interaction with the Crucial C-Terminal Amide of Cholecystokinin by Molecular Modeling, Site-Directed Mutagenesis, and Structure/Affinity Studies Mol. Pharmacol., May 1, 2003; 63(5): 973 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Kopin, E. W. McBride, C. Chen, R. M. Freidinger, D. Chen, C.-M. Zhao, and M. Beinborn Identification of a series of CCK-2 receptor nonpeptide agonists: Sensitivity to stereochemistry and a receptor point mutation PNAS, April 29, 2003; 100(9): 5525 - 5530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pannequin, C. Oiry, C. Morel, J. Kucharczak, I. Camby, R. Kiss, D. Gagne, J.-C. Galleyrand, and J. Martinez C-Terminal Heptapeptide of Gastrin Inhibits Astrocytomas Motility by Interacting with a New Gastrin Binding Site J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 274 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Pommier, F. Beslot, A. Simon, M. Pophillat, T. Matsui, V. Dauge, B. P. Roques, and F. Noble Deletion of CCK2 Receptor in Mice Results in an Upregulation of the Endogenous Opioid System J. Neurosci., March 1, 2002; 22(5): 2005 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lal, A. J. Kirkup, A. M. Brunsden, D. G. Thompson, and D. Grundy Vagal afferent responses to fatty acids of different chain length in the rat Am J Physiol Gastrointest Liver Physiol, October 1, 2001; 281(4): G907 - G915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Malendowicz, M. Nowak, L. Gottardo, C. Tortorella, M. Majchrzak, and G. G. Nussdorfer Cholecystokinin Stimulates Aldosterone Secretion from Dispersed Rat Zona Glomerulosa Cells, Acting Through Cholecystokinin Receptors 1 and 2 Coupled with the Adenylate Cyclase-Dependent Cascade Endocrinology, October 1, 2001; 142(10): 4251 - 4255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Becker, M.-H. Thiebot, Y. Touitou, M. Hamon, F. Cesselin, and J.-J. Benoliel Enhanced Cortical Extracellular Levels of Cholecystokinin-Like Material in a Model of Anticipation of Social Defeat in the Rat J. Neurosci., January 1, 2001; 21(1): 262 - 269. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
